Cited by 117Nuclear Receptors and SignalingEstrogen and related hormone effectsSirtuins and Resveratrol in Medicine

The NR4A subfamily of nuclear receptors: Potential new therapeutic targets for the treatment of inflammatory diseases

Open access
Rodríguez-Calvo, Ricardo, Tajes, Marta, Vázquez-Carrera, Manuel·2017·Expert Opinion on Therapeutic Targets

Abstract

INTRODUCTION: Prolonged inflammatory response contributes to the pathogenesis of chronic disease-related disturbances. Among nuclear receptors (NRs), the orphan NR4A subfamily, which includes Nur77 (NR4A1), Nurr1 (NR4A2) and NOR1 (NR4A3), has recently emerged as a therapeutic target for the treatment of inflammation. Areas covered: This review focuses on the capacity of NR4A receptors to counter-regulate the development of the inflammatory response, with a special focus on the molecular transrepression mechanisms. Expert opinion: Recent studies have highlighted the role of NR4A receptors as significant regulators of the inflammatory response. NR4A receptors are rapidly induced by inflammatory stimuli, thus suggesting that they are required for the initiation of inflammation. Nevertheless, NR4A anti-inflammatory properties indicate that this acute regulation could be a protective reaction aimed at resolving inflammation in the later stages. Therefore, NR4A receptors are involved in a negative feedback mechanism to maintain the inflammatory balance. However, the underlying mechanisms are not entirely clear. Only a small number of NR4A-target genes have been identified, and the transcriptional repression mechanisms are only beginning to emerge. Despite further research is needed to fully understand the role of NR4A receptors in inflammation, these NRs should be considered as targets for new therapeutic approaches to inflammatory diseases.

Integrity signals

Registry

Crossref · 10.1080/14728222.2017.1279146

Cites

158 of 158 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Rodríguez-Calvo, R., Tajes, M., & Vázquez-Carrera, M.
Affiliations
  • Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, Pere Virgili Health Research Institute (IISPV) and Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM)-Instituto de Salud Carlos III, Faculty of Medicine and Health Sciences, Rovira i Virgili University, Reus, Spain
  • Hospital Del Mar (ES)
  • Department of Pharmacology, Toxicology and Therapeutic Chemistry, Institut de Biomedicina de la Universitat de Barcelona (IBUB), Institut de Recerca Pediàtrica-Hospital Sant Joan de Déu, and Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM)-Instituto de Salud Carlos III, Faculty of Pharmacy, Diagonal 643, University of Barcelona, Barcelona, Spain
Venue
Expert Opinion on Therapeutic Targets
Published
2017-01-12
Volume
21
Issue
3
Pages
291-304
ISSN
  • 1472-8222 (ISSN-L)
  • 1744-7631
OpenAlex
W2569529038
Cited by
117
References
158
Citations by year
2026: 6 · 2025: 11 · 2024: 12 · 2023: 9 · 2022: 20 · 2021: 11 · 2020: 21 · 2019: 10 · 2018: 14 · 2017: 1
FWCI
1.55
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Expert Opinion on Therapeutic Targets (publishedVersion)
  • PubMed (publishedVersion)
  • Rovira & Virgili repository (submittedVersion, cc-by)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
Keywords
NR4A nuclear receptors, Nur77, Nurr1, NOR-1, inflammatory diseases, inflammation, transrepression, transcriptional repression, negative feedback regulation, anti-inflammatory mechanism, therapeutic target
MeSH terms
Animals, DNA-Binding Proteins, Humans, Inflammation, Receptors, Steroid, Receptors, Thyroid Hormone, Drug Design, Nuclear Receptor Subfamily 4, Group A, Member 1, Nuclear Receptor Subfamily 4, Group A, Member 2, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review